


2nd International Conference on

Antibodies and Therapeutics

July 11-12, 2016 Philadelphia, USA

Scientific Program



Hall A

conference**series**.com

Opening Ceremony

Keynote Forum

Introduction

Title: Bioinks for 3D Bioprinting: A Development Parameters Review

William George Whitford, GE Healthcare, USA

Title: Display of Influenza Virus Hemagglutinin On Baculovirus Envelope for Antibody Production

Yu-Chan Chao, Academia Sinica, Taiwan

Panel Discussion

Track : Autoimmune Antibodies

Track : Antibody Engineering

Track : Antibodies: Infectious Diseases

Track : Auto Antibodies

Track : Monoclonal Antibodies & Monoclonal Antibody Therapy

Track : Antibodies: Medical Applications

Track : Immunotherapy and Immune Checkpoints

Track : Anti-Cancer Antibodies

Track : Antibody Humanization Technologies

Session Chair: William Whitford, GE Health Care, USA

Session Chair: Yu-Chan Chao, Academia Sinica, Taiwan

Session Introduction

Title: Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides

Ronald James Christie, MedImmune, USA

Panel Discussion

Networking & Refreshments

Title: Exceptionally long CDR3H of bovine scFv antigenized with BoHV-1 B-epitope generates specific immune response against the targeted epitope

Azad K Kaushik, University of Guelph, Canada

Title: Diagnostic challenges in Antiphospholipid Syndrome (APS), or Hughes Syndrome

Ljudmila Stojanovich, Belgrade University, Serbia

Title: Discovery of cancer neoantigens by high throughput capture of the human antibody repertoire from checkpoint inhibitor responsive cancer patients enables creation of novel mAb-targeted cancer immunotherapies

Scott K Dessain, Immunome, Inc., USA

Title: Tumor microenvironment associated immune cells mediate platelet-activating factor induced tumor growth and treatment effectiveness

Ravi P Sahu, Wright State University, USA

Panel Discussion

Lunch Break

Title: Tumor specific antigen targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against malignancies

Juan Zhang, China Pharmaceutical University, China

Title: Rapid production of bispecific antibodies using 'off-the-shelf' IgG

Andrew Tsourkas, University of Pennsylvania, USA

Title: Mimtags: The usage of phage display technology to produce novel protein-specific probes

Cenk Suphioglu, Deakin University, Australia

Preferential germline usage and VH/VL pairing observed in human antibodies selected by mRNA display

Lei Chen, AbbVie Bioresearch Center, USA

Local antibody as a correlate of protection against influenza infection

John Tregoning, Imperial College London, UK

3D1, a novel anti-nodal monoclonal antibody to target melanoma

Annamaria Sandomenico, Institute of Biostructure and Bioimaging, Italy

i-bodies: Novel single domain antibodies against GPCRs and Ion channels in the treatment of fibrosis

Michael Foley, La Trobe University, Australia

Anti-inflammatory activity of a CD44 variant-specific antibody and the CD44 variant derived peptide

David Naor, The Hebrew University-Hadassah Medical School, Israel

Antibodies are not required to a protective immune response against dengue virus elicited in a mouse encephalitis model

Jaime Henrique Amorim, Universidade Federal do Oeste da Bahia, Brazil

Diagnostic accuracy of anti-gliadin antibodies in non celiac gluten sensitivity (NCGS) Patients: A novel statistical evaluation

Maria Infantino, Florence Health Agency Hospital, Italy

Comparative investigations for adenovirus quantification: Plastic or natural antibodies?

I E Tothill, Cranfield University, UK

Myeloid-derived suppressor cells are closely associated with disease progression in patients with HBV-related acute-on-chronic liver failure

Chaoshuang Lin, Sun Yat-sen University, China

Immuno-capture LC-MS/MS hybrid assay methodology in ADC bioanalysis

Ang Liu, Bristol-Myers Squibb, USA

Panel Discussion

Day 2

July 12, 2016

Hall A

Keynote Forum

Introduction

Title: The Trianni Mouse — the next generation transgenic platform for the isolation of fully human monoclonal antibodies

David Meininger, TRIANNI, USA

Title: Round Table on Upstream Continuous Manufacturing Equipment and Materials

William George Whitford, GE Health Care, USA

Panel Discussion

Networking & Refreshments

Track : Antibodies: Medical Applications

Track : Immunotherapy and Immune Checkpoints

Track : Anti-Cancer Antibodies

Track : Antibody Humanization Technologies

Track : Biomarkers Development

Session Chair: William Whitford, GE Health Care, USA

Session Chair: Yu-Chan Chao, Academia Sinica, Taiwan

Session Introduction

Title: Multiparameter autoantibody screening in the diagnosis of neurological autoimmune diseases

Winfried Stöcker, Euroimmun AG, Germany

Title: Plant-based expression of therapeutic monoclonal antibodies targeting viral and bacterial infections

Jerzy Karczewski, Fraunhofer USA

Title: Characterization of a PEGylated single-domain antibody

Lumelle Schneeweis, Bristol-Myers Squibb, USA

Title: The presence of interleukin 18 binding protein auto-antibodies and isoforms in chinese patients with rheumatoid arthritis

K E Khalid, Albaha University, Albaha-Saudi Arabia

Immunomics using protein-and peptide microarrays for cancer biomarker development

Andreas Weinhäusel, Austrian Institute of Technology, Austria

Biosimilars in rheumatology practice: Where we stand?

Reem Hamdy A Mohammed, Cairo University, Egypt

Humanized mouse G6 anti-idiotypic monoclonal antibody has therapeutic potential against IGHV169 germline gene based B-CLL

De-Kuan Changm, Dana-Farber Cancer Institute, USA

Therapeutic monoclonal antibodies: What headache specialists need to know?

Stephen Silberstein, Jefferson Headache Center, USA

Disaccharide mimics as drugs against cancer and epitopes for anti-cancer vaccine candidates

Pierre Vogel, Swiss Institute of Technology in Lausanne, Switzerland

Development of a monoclonal antibody based indirect competitive enzyme-linked immunosorbent assay for nitroimidazoles in edible animal tissues and feeds

Dapeng Peng, Huazhong Agricultural University, China

Subsequent entry biologic (biosimilar) monoclonal antibodies in Canada: A review of key regulatory issues and lessons learned

Bradley Scott, Biologics and Genetic Therapies Directorate, Canada

Expression of CD31 and CD34 in oral squamous cell carcinoma development and metastasis

Bouguezzi A, University Dental Clinic of Monastir, Tunisia

High affinity anti-Internalin B VHH antibody fragments isolated from naturally and artificially immunized repertoires

Mehdi Arbabi Ghahroudi, National Research Council Canada, Canada

Panel Discussion

Lunch Break

Award Ceremony

Bookmark your dates

3rd Antibodies & Bio Therapeutics Congress

November 02-03, 2017 Las Vegas, USA

e-mail: contact@immunologyconferences.com; antibodies@conferenceseries.net; walker.smith@conferenceseries.com

Website: antibodies.conferenceseries.com